aTYR PHARMA INC (ATYR) has 11 open-market insider trades by 6 insiders since 2017. Over the last six months insiders net bought $50K. The most active filer is Paul Schimmel, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Paul Schimmel | Dir | — | 3 | $2.1M | 2026-05-27 |
| EcoR1 Capital Fund Qualified, L.P. | 10% Owner | — | 1 | $318K | 2017-11-13 |
| Jane A. Gross | Dir | — | 1 | $15K | 2025-03-17 |
| Nancy Denyes | General Counsel | — | 3 | $14K | 2026-02-04 |
| Jill Marie Broadfoot | CFO | — | 2 | $6K | 2026-02-04 |
| Sanjay Shukla | CEOPres | — | 1 | $4K | 2026-02-04 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Paul Schimmel | Director | Buy | $50K | 2026-05-27 |
| Sanjay Shukla | CEO & President | Sell | $4K | 2026-02-04 |
| Nancy Denyes | General Counsel | Sell | $1K | 2026-02-04 |
| Jill Marie Broadfoot | CFO | Sell | $2K | 2026-02-04 |
| Paul Schimmel | Director | Buy | $1.8M | 2025-10-08 |
| Jane A. Gross | Director | Buy | $15K | 2025-03-17 |
Companies that share insiders with ATYR, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Jill Marie Broadfoot | CFO | Sell | $5K | 2025-02-04 |
| Nancy Denyes | General Counsel | Sell | $3K | 2025-02-04 |
| Paul Schimmel | Director | Buy | $256K | 2024-07-22 |
| Nancy Denyes | General Counsel | Buy | $9K | 2024-06-05 |
| EcoR1 Capital Fund Qualified, L.P. | 10% | Sell | $56K | 2017-11-08 |
| EcoR1 Capital Fund Qualified, L.P. | 10% Owner | Buy | $262K | 2017-10-01 |